With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP and Head of Therapeutic Area Biosimilars, Ivan Blanarik, to find out more…
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
What is a biosimilar and how does it relate to a biologic?
A biosimilar is a highly similar version of an approved biologic, the so-called “reference product”.
Made from living organisms, biologics are proteins – often antibodies – that interact with the body to produce a therapeutic outcome.
Unlike small molecule drugs that are chemically synthesised and can be copied exactly to produce a generic drug, biologics, including biosimilars are large, complex molecules that are manufactured in living cells and then extracted and purified.
Because any given biologic is inherently variable, it is impossible to develop an identical copy of that biologic (the reference product). However, the biosimilar and the reference product are very similar and work in the same way with no clinically meaningful differences in terms of quality, safety and efficacy.
Can you tell us about the development process of biosimilars?
Biosimilars are developed and evaluated using rigorous processes, involving detailed analytical and functional studies, non-clinical assessments, and clinical trials. Given the very complex structure of these molecules, developing biosimilars requires a high degree of technical expertise.
The clinical trials carried out on a potential biosimilar are designed differently to those for approval of a novel biologic. When assessing a potential biosimilar, the aim is to confirm that there are no clinically meaningful differences in its efficacy and safety compared to the reference product. Biosimilar approval is based on the totality of data demonstrating similarity between the biosimilar and the reference product, including quality characteristics, biological activity, safety, and efficacy.
Because of this complexity, there is a significant difference between the development of a generic drug and a biosimilar: on average, a generic drug takes 3-5 years to develop at a cost of USD $1-5 million; a biosimilar, on the other hand, takes on average 7-8 years to develop at a cost of USD $100-250 million.
What are the benefits of biosimilars to the healthcare community and what excites you the most about their development?
Biosimilars have the potential to deliver significant benefits to the healthcare community. These include, expanding overall treatment options and positively impacting the lives of patients suffering from life-threatening or chronic diseases, such as cancer or rheumatoid arthritis, whilst contributing to the quality and financial sustainability of healthcare systems.
From my perspective, the development of biosimilar candidates opens a new and exciting form of innovation in the biopharmaceutical sector. The introduction of biosimilars redefines what it means to be innovative for a pharmaceutical company.
What new developments are currently happening with biosimilars?
Firstly, it’s worth highlighting that the technology involved in manufacturing and characterisation of biologics has advanced significantly. Manufacturers are now able to develop highly detailed characterisations of the molecular and functional attributes of products, including tracing potential product impurities, uniformity, and concentration. This allows for a multi-level assessment of the purity, safety, and potency of biological products.
Secondly, the worldwide expenditure on biologic drugs keeps growing. The biologics market is predicted to continue to grow faster than the total pharma market and is expected to account for almost 30% of global prescription sales by 2020. Interestingly, according to some analysts, by 2020 biosimilars will comprise between 4% and 10% of the total biologics market, with their market value expected to exceed $25 billion.
We are seeing more and more biosimilar approvals by the European Medicines Agency (EMA) across all indications, and these are set to expand even further in 2017 – currently there are 22 biosimilars approved in the region – so this really is a very exciting time to be working in this space.
What is the future of biosimilars?
For biosimilars to realise their full potential to benefit healthcare providers and patients alike, it is more critical than ever before to understand these audiences and their needs. This is crucial for the development and delivery of new and effective solutions that will have the greatest impact for both patients and healthcare providers.
As key players in the healthcare community, we – the pharmaceutical industry – need to be thinking about adding value beyond the product itself by proactively seeking innovative partnerships to improve the experience of patients, providers and payers with biologics.
I believe that by taking this collaborative approach, we can utilise our wide wealth of capabilities to deliver healthcare solutions for patients that need them most, today and in the future.
Biography
Ivan Blanarik is Senior Vice President and Global Lead of the Biosimilar Therapeutic Area at German-owned pharmaceutical company Boehringer Ingelheim.
Ivan has extensive experience in the pharmaceutical industry, having spent the last 20 years in different positions in Sales and Marketing and General Management both in Mature and Emerging markets. His last assignments have been as Head of Boehringer Ingelheim’s Prescription Medicine unit in Portugal, Managing Director of Boehringer Ingelheim Finland and Country Managing Director of Boehringer Ingelheim Russia – overseeing Prescription Medicine, Consumer Health Care and Animal Health businesses.
Ivan holds a degree in Clinical Pharmacy and Business Administration and his main areas of expertise are Development and Implementation of business strategy, organisational design and transformation and innovative business models.
Excellent article, especially the future is well explained. Biosimilar R & D needs huge capex and high skills, but however better returns are expected. The investments in Biosimilar development has also boosted other industries like bioreactor designer, online biochemical analysing equipment manufacturers, media manufacturers etc. These are good parallel effects.
Interest in biosimilar protein drugs continues to grow, however, molecular structures of biosimilars are so complex. But with high-quality analysis coupled with the clinical trial data, the bio-similarity to the reference product can be demonstrated. While we can show the similarity in a molecule’s chemical and biological identity, we still need to demonstrate that each biosimilar can act as a pharmaceutical drug with the same amount of clinical safety and effectiveness as the original. All of these factors can significantly slow down the timeline to approval and production.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Excellent article, especially the future is well explained. Biosimilar R & D needs huge capex and high skills, but however better returns are expected. The investments in Biosimilar development has also boosted other industries like bioreactor designer, online biochemical analysing equipment manufacturers, media manufacturers etc. These are good parallel effects.
Interest in biosimilar protein drugs continues to grow, however, molecular structures of biosimilars are so complex. But with high-quality analysis coupled with the clinical trial data, the bio-similarity to the reference product can be demonstrated. While we can show the similarity in a molecule’s chemical and biological identity, we still need to demonstrate that each biosimilar can act as a pharmaceutical drug with the same amount of clinical safety and effectiveness as the original. All of these factors can significantly slow down the timeline to approval and production.